The 12mos. P-IIIb (V-INITIATE) study assesses the efficacy of earlier Leqvio addition vs usual care in ASCVD patients (n= 450) with LDL-C ≥70 mg/dL in spite of receiving maximally tolerated statin therapy across the US
The study demonstrated LDL-C reductions in 60% vs 7% of patients (73% of them consisted statin therapy alone), LDL-C <70 mg/dL was observed in 81.8% vs 22.2% of them and 5.8% vs 16.7% of them maintained adherence to lipid-lowering therapy with similar rates of statin discontinuation
The safety profile was consistent with the previous P-III (ORION-3 and ORION-8) trials showing sustained safety for up to 6yrs.
Ref: Novartis | Image: Novartis
Related Post:- Novartis Leqvio (inclisiran) Receives the US FDA’s Approval for the Treatment of Atherosclerotic Cardiovascular Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
